Hexarelin

Quick Facts

Introduction

Hexarelin is a synthetic hexapeptide belonging to the growth-hormone-releasing peptide (GHRP) family — the small ghrelin-mimetic molecules that stimulate the pituitary to release growth hormone. Among the classic GHRPs it is regarded as one of the most potent growth-hormone releasers, and it is studied alongside its relatives GHRP-2, GHRP-6, and the selective Ipamorelin.

Like the rest of its class, hexarelin engages the growth-hormone secretagogue receptor (GHS-R1a) rather than the GHRH receptor used by analogues such as CJC-1295 and Sermorelin. What sets hexarelin apart within the GHRP family is a distinct secondary research interest in cardiovascular biology: it interacts with the scavenger receptor CD36, a property studied for growth-hormone-independent effects on the heart.

This profile covers what hexarelin is, its molecular characteristics, its dual GHS-R1a / CD36 mechanism, the growth-hormone and cardiovascular research it appears in, and how it compares with related secretagogues. Related compounds are catalogued in the peptide database, and the broader class is summarized in the research library.

What is Hexarelin?

Hexarelin (sometimes called examorelin) is a synthetic ghrelin-mimetic hexapeptide derived from the GHRP-6 scaffold. A single key modification — methylation of the tryptophan residue — increases its potency and metabolic stability relative to the parent compound, making it one of the strongest growth-hormone secretagogues in the classic GHRP series.

Like other GHRPs, hexarelin condenses the receptor-activating chemistry of ghrelin into six residues built partly from D-amino acids and an unnatural methylated tryptophan. These non-natural building blocks slow enzymatic degradation, giving the molecule a more practical stability profile than native ghrelin while preserving robust GHS-receptor activity.

Because hexarelin works upstream of growth hormone — prompting the pituitary to release its own stored hormone rather than supplying exogenous GH — the resulting secretion preserves the pulsatile pattern of the natural axis. Its additional affinity for the CD36 receptor is the feature that distinguishes its research profile from the purely somatotropic secretagogues.

Molecular and structural characteristics

Hexarelin has the sequence His-2-methyl-D-Trp-Ala-Trp-D-Phe-Lys-NH₂, a C-terminally amidated hexapeptide closely related to GHRP-6. The defining structural difference is the methylation of the second-position tryptophan, a change associated with its enhanced potency and resistance to peptidase degradation. The aromatic residues remain central to GHS-receptor engagement.

Its small, well-defined sequence makes hexarelin a convenient and reproducible research tool. The amidated C-terminus, the bulky aromatic side chains, and the methylated tryptophan together define the pharmacophore recognized by both the GHS-R1a and, in cardiovascular research, the CD36 receptor.

Mechanism of action

Hexarelin's primary action is agonism at the growth-hormone secretagogue receptor (GHS-R1a), a G-protein-coupled receptor on pituitary somatotrophs and in the hypothalamus. Receptor activation engages the Gq/phospholipase-C pathway, raising intracellular calcium and triggering the release of stored growth hormone. Among the classic GHRPs, hexarelin is associated with a particularly strong GH-releasing response.

Because the GHS receptor is distinct from the GHRH receptor, hexarelin is studied for synergy with GHRH analogues; combining the two pathways is reported to produce a larger, coordinated growth-hormone pulse than either compound alone. Hexarelin also amplifies GH output partly by opposing somatostatin, the inhibitory hypothalamic brake on GH release. The downstream consequence is elevation of hepatic insulin-like growth factor 1 (IGF-1).

Hexarelin's distinctive second mechanism is its interaction with the scavenger receptor CD36, which is expressed in cardiac and vascular tissue. This GHS-R1a-independent pathway is the basis for research into growth-hormone-independent cardiovascular effects, a line of investigation that separates hexarelin from purely somatotropic secretagogues such as Ipamorelin.

• GHS-R1a (ghrelin-receptor) agonism on pituitary somatotrophs.
• Gq/phospholipase-C signaling and intracellular calcium rise.
• Strong stimulation of pulsatile growth-hormone release.
• Partial opposition of somatostatin tone.
• CD36-mediated, GH-independent cardiovascular signaling.

Growth-hormone axis research

The core research context for hexarelin is the GH/IGF-1 axis. In preclinical models and study populations, hexarelin has been associated with potent, dose-related increases in circulating growth hormone, and it has been used as a probe in growth-hormone stimulation research. Investigators also note a tendency toward desensitization of the GH response with continued exposure — itself an informative feature for studying GHS-receptor regulation.

Researchers contrast hexarelin's high potency with the later GHRP-2, the original GHRP-6, and the more selective Ipamorelin, which releases growth hormone with minimal effect on cortisol and prolactin. Hexarelin sits in the same conceptual conversation as GHRH analogues such as Tesamorelin and CJC-1295.

Cardiovascular and CD36 research

Hexarelin's most distinctive line of research concerns the cardiovascular system. Beyond the pituitary, the GHS receptor and the scavenger receptor CD36 are present in cardiac and vascular tissue, and preclinical models have examined hexarelin for growth-hormone-independent cardioprotective signaling — effects observed even when growth-hormone release is controlled for. This positions hexarelin uniquely among the GHRPs, whose research is otherwise dominated by the GH axis.

These cardiovascular observations are reported in animal and tissue models and are described here strictly as research findings, not as evidence of therapeutic benefit. The dual GHS-R1a / CD36 pharmacology nevertheless makes hexarelin a valuable tool compound for dissecting the broader physiology of the growth-hormone secretagogue receptor family.

Comparison: Hexarelin vs GHRP-2 vs Ipamorelin

Hexarelin is most often compared with the other ghrelin-mimetic secretagogues. GHRP-2 is a potent GH-releaser with a modest appetite effect; Ipamorelin is a selective pentapeptide reported to spare cortisol and prolactin. All three act through the GHS receptor, but hexarelin is distinguished by its high potency and its additional CD36-mediated cardiovascular pharmacology.

Researchers frequently pair a GHRP with a GHRH analogue because their receptors are complementary — for example studying hexarelin together with CJC-1295. Full entries for each compound are in the peptide database.

Half-life and pharmacokinetic considerations

Hexarelin is a short-acting peptide. Its growth-hormone-releasing effect is rapid in onset and transient, with a plasma half-life on the order of tens of minutes — consistent with its role as a provocative stimulus that produces a discrete GH pulse rather than a sustained elevation. Its methylated structure contributes to slightly greater metabolic stability than the parent GHRP-6.

A notable pharmacodynamic feature is attenuation of the GH response with repeated or prolonged exposure, which researchers attribute to receptor desensitization. This makes the timing and frequency of exposure an important interpretive variable in hexarelin studies, distinguishing it from long-duration GHRH analogues such as the DAC form of CJC-1295.

Reconstitution and handling considerations

Hexarelin is supplied as a lyophilized powder and reconstituted with sterile or bacteriostatic water, added slowly down the vial wall and swirled gently rather than shaken to protect the peptide. The reconstituted solution should be clear; cloudiness or particulates indicate it should be discarded.

Working concentration is selected so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent slowly; swirl gently rather than shaking.
• Confirm the solution is clear before use.
• Protect from light and excess warmth.
• Avoid repeated freeze–thaw cycles of reconstituted material.

Storage considerations

Lyophilized hexarelin is most stable frozen at −20 °C, kept dry and away from light. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window; aliquoting reduces how often a given solution is cycled.

Research limitations

Hexarelin is a research compound. Although its GHS-receptor biology and CD36 interaction are comparatively well characterized, much hexarelin-specific data come from short-term studies, provocative-testing protocols, or animal models, and reported effects are dose-, route-, and design-dependent. The desensitization of the GH response with continued exposure, and the translational relevance of the cardiovascular findings, remain active research questions. It is described here strictly for research reference.

• The GH response may attenuate with repeated exposure (desensitization).
• Cardiovascular findings are largely from preclinical models.
• Reported effects are dose-, route-, and design-dependent.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660.Source
2. Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977.Source
3. Locatelli V, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999.